People with Parkinson’s disease have a nearly twofold higher risk of developing osteoporosis, a chronic condition marked by increased bone fragility, than healthy people, a study showed. Besides identifying for the first time Parkinson’s as an independent risk factor for osteoporosis, the researchers found five genes with diagnostic and…
Levels of the GFAP protein in blood are significantly higher in Parkinson’s disease patients with cognitive impairment — particularly those with dementia — compared with healthy people, a new study shows. According to researchers, blood GFAP levels could accurately identify Parkinson’s patients with mild cognitive impairment (MCI) who ended…
Different types of hallucinations — hearing voices, feeling a touch, and detecting smells or tastes, among others — affect a large proportion of people with Parkinson’s disease and have substantial clinical importance, according to a new review study. While visual hallucinations are a known nonmotor symptom of the neurodegenerative…
A new device called Izar that aims to help assess and train hand function for people with neurological disorders such as Parkinson’s disease is now available in the U.S., as well as in European countries including France, Switzerland, and Germany. According to its manufacturer, MindMaze, the hand-sized device is…
Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for Parkinson’s disease. The funding comes in the form of a Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM). Ryne plans to use the award…
Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test its experimental oral medication CVN424 in people newly diagnosed with Parkinson’s disease. The company announced $51 million in new funding, from an expanded round of Series B Financing, for…
“Parkinson’s Science POV,” a limited series podcast by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has garnered silver and Listener’s Choice honors at the Signal Awards’ inaugural program. The awards, honoring top 2022 podcasts globally, recognized the Parkinson’s disease series within its Science & Education category for “Limited Series…
Scientists have identified potential biomarkers for the early detection of Parkinson’s disease in certain people carrying a common disease mutation. Specifically, they found that a combination of four small RNA molecules, called microRNAs (miRNAs), in the blood may help predict disease onset in people who carry a Parkinson’s-associated LRRK2…
IntelGenx has teamed up with a renowned neurologist at the Karolinska Institute, Sweden to conduct a clinical trial on Montelukast VersaFilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The multicenter trial, expected to start between July and September, will be led by Per Svenningsson,…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $2.5 million research grant to advance the development of Soturi, Newel Health’s digital therapeutic app designed to help patients optimize their personalized treatment plan. The Soturi app is designed to deliver services to people with…
Get regular updates to your inbox.